New Publication – Adhesion of meticillin-resistant Staphylococcus aureus to DACC-coated dressings
SUMMARY OF IN VITRO BINDING PUBLICATION – link to the whole article above.
A.C. Ronner, J. Curtin, N. Karami, and U. Ronner. Adhesion of meticillin-resistant Staphylococcus aureus to DACC-coated dressings.
The above study was performed at Sahlgrenska Science Park, Gothenburg University in Sweden and was aimed to demonstrate comparable binding of clinical Staphylococcus aureus strains relative to multiple MRSA strains using a DACC-coated dressing as an adhesion material. Eleven isolates were used in this study. The MRSA strains were isolated from different inpatient and outpatient wounds. All the MRSA isolates in the study were clinical in origin and caused infection in the patients seeking treatment.
To study the binding of bacteria to the dressing surface, an inoculum of each strain was added to the wound dressing. After an opportunity for bacteria binding was afforded, each sample dressing was rinsed multiple times to ensure the release of loosely adhered cells. The number of bacteria adhering to the dressing were then determined by a standardized luminescence technique for ATP detection.Eleven strains of Staphylococcus aureus were examined including 9 x MRSA, all of which efficiently and equally adhered to the DACC-coated dressing. The binding capacity was in the same range 0.7–2.9×106 CFU/cm2 regardless of the antibiotic resistance properties of the specific strain. A comparison of the adhesion capacity between a DACC-coated dressing material and an uncoated control with the Staphylococcus aureus control strain was performed. The DACC-coated material bound a mean value of 1.5×106 CFU/cm2, whereas uncoated binding was reduced to a mean value of 6.8×104 CFU/cm2, which was significantly lower (p<0.0001).
The decrease of wound bioburden of Staphylococcus aureus including MRSA is the result of the high binding capacity shown in this study and by earlier data. The findings in this study strengthen the held view that development of antibiotic resistance has minimal impact on the surface structures of the microorganisms in wounds.
Further clinical work is intended to follow this study with the intention to demonstrate early involvement of Sorbact® in the management of wounds (in both open wound management and surgical site infection prevention) will enhance wound outcomes and relieve the burden placed upon antibiotics.